Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The New England Journal of Medicine|February 15, 2013
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerAlan L Ho, Ravinder K Grewal, Rebecca Leboeuf, et al.
Thyroid : Official Journal of the American Thyroid Association|January 20, 2022
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical TrialVatche Tchekmedyian, Lara Dunn, Eric Sherman, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersLara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.
Neuro-Oncology|November 19, 2024
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group studyMatthias A Karajannis, Arzu Onar-Thomas, Tong Lin, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
Neuro-Oncology|February 11, 2022
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patientsAlexandra M Miller, Luca Szalontay, Nancy Bouvier, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
Nature Medicine|August 24, 2023
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trialJoris L Vos, Bharat Burman, Swati Jain, et al.
Pageof 5